Viking Therapeutics, Inc. (VKTX) financials

NASDAQ · Healthcare · Biotechnology · 53 employees · CEO Brian Lian

Price: $27.28 +1.56%
Market cap: $3.48B
Enterprise value: $3.06B
Last report: Q3 '26 filed 2026-10-29
Next report: 2027-02-10 EPS est. -$1.38

Revenue (TTM)$0– vs a year agoLast 4 quarters; bars = each quarter

Operating margin (TTM)–– vs a year agoOperating income -$649M

Net income (TTM)-$627M-164.2% vs a year agoAfter tax, incl. non-operating gains

Free cash flow (TTM)-$463M-106.0% vs a year agoCapex $0

Diluted EPS (TTM)-$5.40-154.7% vs a year agoSum of the last 4 quarters

Net cash$705M-1.2% vs a year agoCash + short-term investments - debt

Valuation & key figures

Market cap: $3.48B
Revenue: $0
Revenue growth: –
Profit margin: –
P/E: -5.1×
P/S: 0.0×
EV / EBITDA: -4.9×
Free cash flow: -$463M
Net income: -$627M
Revenue estimate: $7.17M
Earnings: 2027-02-10
Dividend: –

Key takeaways

Computed from the reported numbers - every statement carries the figure it rests on.

Last report (2026-10-28): revenue n/a, EPS missed by 46.2%Revenue – vs – expected (–); EPS -$1.55 vs -$1.06 (-46.2%).
Diluted share count up 5.1% in a year118M diluted shares in Q3 '26, 112M a year earlier.
Net cash $705MCash + short-term investments $960M, debt incl. leases $255M; a year ago net cash $714M.

Last quarter: Q3 '26

Quarter ended 2026-09-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.

Quarter vs a year ago

	Q3 '26	Year ago	Change
Revenue	$0	$0	–
Operating income	-$187M	-$98.6M	-89.8%
Net income	-$183M	-$90.8M	-101.8%
Diluted EPS	-$1.55	-$0.81	-91.4%
Operating cash flow	-$138M	-$94M	-47.0%
Capex	$0	$0	–
Free cash flow	-$138M	-$94M	-47.0%
R&D	$167M	$90M	+85.4%
Stock-based compensation	$17.9M	$7.34M	+143.9%

Reported vs consensus

2026-10-28

	Actual	Consensus	vs consensus
EPS (as estimated)	-$1.55	-$1.06	-46.2%

From the report of 2026-10-28 for Q3 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.

EPS vs consensus

last 8 reports

Revenue

Where the money comes from - by business line and by region, quarter by quarter.

Revenue, operating income and growth

quarterly

Margins & cost structure

How much of each unit of revenue is left at each level - and where the costs go.

Margins

quarterly

Costs as % of revenue

quarterly

Cash flow & capital allocation

Cash generated, what it is spent on, and what reaches shareholders.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Last 4 quarters

cash flow statement

Operating cash flow: -$463M
Capex: $0
Buybacks: $0
Dividends: $0
Acquisitions: $0
Net debt issued: $251M
Stock-based compensation: $47.9M
Free cash flow: -$463M
Returned to shareholders / FCF: 0.0%

Share count and EPS

quarterly, diluted

Balance sheet

Liquidity, investments and debt at each quarter end.

Cash, investments and debt

quarter ends

Valuation & returns

Today's multiples against the company's own last five fiscal years; analyst targets and ratings.

Multiples and returns

TTM vs 5 fiscal years

	Now	5y average	Where today sits in the 5-year range
P/E (TTM)	-5.1×	–	–
EV / EBITDA	-4.9×	–	–
EV / Sales	0.0×	–	–
Price / FCF	-7.5×	–	–
Price / Book	5.5×	4.6×	1.8× – 6.2×
FCF yield	-13.3%	-6.7%	-13.4% – -2.0%
Return on invested capital	-76.9%	-36.6%	-61.5% – -17.1%
Return on equity	-117.3%	-33.6%	-56.3% – -12.5%

Analysts

Consensus target $82.00 (+200.6%)
range $34.00 – $120.00 · rating Buy

Strong buy1

Buy22

Hold1

Sell0

Strong sell0

Outlook

Analyst consensus for the coming fiscal years and what it implies at today's price.

Consensus estimates

Fiscal year	Revenue	Growth	EPS	Growth	P/E at today's price	Analysts (EPS)
FY2026	$7.17M	–	-$5.32	-66.7%	-5.1×	13
FY2027	$7.35M	+2.5%	-$5.15	+3.2%	-5.3×	15
FY2028	$217M	+2,854.9%	-$3.93	+23.6%	-6.9×	15
FY2029	$483M	+122.2%	-$1.69	+57.0%	-16.1×	9
FY2030	$1.15B	+138.2%	$1.66	+198.4%	16.4×	6

Financial statements

Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.

Income statementRevenue, costs, operating income, net income and EPSOpen Balance sheetCash, investments, assets, debt, liabilities and equityOpen Cash flowOperating cash flow, capex, free cash flow, buybacks and dividendsOpen

Every reported line

All 161 figures Viking Therapeutics, Inc. tagged in its recent 10-Q / 10-K filings, with the official SEC label and definition - including the notes (leases, taxes, buybacks, employees, ...).

Line (SEC label)	Latest quarter	Year ago	y/y	Latest FY	Prior FY	y/y
	$88K	$0	–	–	–	–
Accounts Payable, Current	$82.1M	$4.41M	+1,761.2%	$53.3M	$9.81M	+442.7%
Accretion (Amortization) of Discounts and Premiums, Investments	$796K	$2.03M	-60.8%	$9.28M	$17.3M	-46.2%
Additional Paid in Capital, Common Stock	$1.91B	$1.4B	+36.0%	$1.49B	$1.37B	+8.6%
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4.82M	-149K	+3,322.7%	7.35M	7.45M	-1.4%
AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax	-$1.7M	$374K	-554.0%	$378K	-$788K	+148.0%
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	$17.9M	$7.34M	+143.9%	$40.8M	$29.7M	+37.4%
Assets	$977M	$739M	+32.2%	$716M	$908M	-21.2%
Assets, Current	$973M	$739M	+31.7%	$716M	$907M	-21.1%
Assets, Fair Value Disclosure	$836M	$683M	+22.3%	$599M	$895M	-33.0%
Cash and Cash Equivalents, at Carrying Value	$678M	$100M	+575.1%	$166M	$26.7M	+521.6%
Cash and Cash Equivalents, Fair Value Disclosure	$553M	$68.8M	+703.7%	$59.1M	$18.6M	+218.0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$678M	$100M	+575.3%	$166M	$26.7M	+521.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect	$552M	$66.5M	+729.9%	$139M	-$28.7M	+585.0%
Common Stock, Capital Shares Reserved for Future Issuance	23.6M2025-12-31	24.7M	-4.4%	23.6M	24.7M	-4.4%
Common Stock, Par or Stated Value Per Share	$0.00	$0.00	0.0%	$0.00	$0.00	0.0%
Common Stock, Shares Authorized	300M	300M	0.0%	300M	300M	0.0%
Common Stock, Shares, Issued	128M	112M	+13.4%	115M	112M	+2.9%
Common Stock, Shares, Outstanding	128M	112M	+13.4%	115M	112M	+2.9%
Common Stock, Value, Issued	$1K	$1K	0.0%	$1K	$1K	0.0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$184M	-$90.2M	-103.6%	-$358M	-$110M	-224.8%
Convertible Notes Payable, Noncurrent	$251M	–	–	$2.15M2015-12-31	$1.26M	+70.2%
Current Federal Tax Expense (Benefit)	–	–	–	$0	$0	–
Current Federal, State and Local, Tax Expense (Benefit)	–	–	–	$1K	$1K	0.0%
Current State and Local Tax Expense (Benefit)	–	–	–	$1K	$1K	0.0%
Debt Securities, Available-for-sale	$282M	$614M	-54.1%	$540M	$876M	-38.4%
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	$1K	$1.01M	-99.9%	$932K	$802K	+16.2%
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	$1.22M	$144K	+750.0%	$88K	$1.08M	-91.8%
Debt Securities, Available-for-sale, Amortized Cost	$283M	$613M	-53.8%	$539M	$876M	-38.5%
Debt Securities, Available-for-sale, Current	$282M	$614M	-54.1%	$540M	$876M	-38.4%
Debt Securities, Available-for-sale, Gain (Loss)	$02026-03-31	–	–	–	–	–
Debt Securities, Available-for-sale, Realized Gain (Loss)	–	–	–	$10K	–	–
Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions	113 Security	82 Security	+37.8%	59 Security	132 Security	-55.3%
Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance	–	–	–	1M2014-02-28	–	–
Deferred Federal Income Tax Expense (Benefit)	–	–	–	-$60.4M	-$33.2M	-81.9%
Deferred Federal, State and Local, Tax Expense (Benefit)	–	–	–	-$101M	-$45.1M	-123.2%
Deferred Foreign Income Tax Expense (Benefit)	–	–	–	-$19.6M	$0	–
Deferred State and Local Income Tax Expense (Benefit)	–	–	–	-$20.8M	-$11.9M	-74.0%
Deferred Tax Assets, Goodwill and Intangible Assets	$134M2025-12-31	$93.1M	+44.1%	$134M	$93.1M	+44.1%
Deferred Tax Assets, Gross	$265M2025-12-31	$164M	+61.2%	$265M	$164M	+61.2%
Deferred Tax Assets, Net	$02025-12-31	$0	–	$0	$0	–
Deferred Tax Assets, Net of Valuation Allowance	$247K2025-12-31	$281K	-12.1%	$247K	$281K	-12.1%
Deferred Tax Assets, Operating Loss Carryforwards	$68.2M2025-12-31	$40.8M	+67.1%	$68.2M	$40.8M	+67.1%
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$195M2025-12-31	$158M	+23.4%	$195M	$158M	+23.4%
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	$156M2025-12-31	–	–	$156M	–	–
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	$111M2025-12-31	$110M	+0.9%	$111M	$110M	+0.9%
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	$17.7M2025-12-31	$17.8M	-0.6%	$17.7M	$17.8M	-0.6%
Deferred Tax Assets, Other	$02025-12-31	$91K	-100.0%	$0	$91K	-100.0%
Deferred Tax Assets, Tax Credit Carryforwards, Research	$58.3M2025-12-31	$27.2M	+114.2%	$58.3M	$27.2M	+114.2%
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	$4.24M2025-12-31	$2.8M	+51.5%	$4.24M	$2.8M	+51.5%
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities	$174K2025-12-31	$403K	-56.8%	$174K	$403K	-56.8%
Deferred Tax Assets, Valuation Allowance	$265M2025-12-31	$164M	+61.4%	$265M	$164M	+61.4%
Deferred Tax Liabilities, Net	$247K2025-12-31	$281K	-12.1%	$247K	$281K	-12.1%
Deferred Tax Liabilities, Other	$223K2025-12-31	$0	–	$223K	$0	–
Deposits Assets, Noncurrent	$113K	$46K	+145.7%	$46K	$46K	0.0%
Earnings Per Share, Basic	-$1.55	-$0.81	-91.4%	-$3.19	-$1.01	-215.8%
Earnings Per Share, Diluted	-$1.55	-$0.81	-91.4%	-$3.19	-$1.01	-215.8%
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	-$26K	-$6K	-333.3%	-$8K	-$148K	+94.6%
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	–	–	–	-$75.5M	–	–
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	–	–	–	21.0%	21.0%	0.0%

Source: SEC companyfacts (XBRL of every 10-Q / 10-K). Cash-flow quarters are derived from the year-to-date figures the 10-Q tags. Segment breakdowns are tagged with dimensions and are shown in the segment section instead.

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30

Data as of 2026-11-02